This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Autoimmune disease

Multiple sclerosis (MS)

Potassium channel K2p2.1 (KCNK2;
TREK-1)

Mouse studies suggest TREK-1 activation could help treat disorders involving blood brain barrier (BBB) dysfunction, such as MS. In Trek-1-/- mice, leukocyte infiltration across the BBB into the CNS was greater than that in wild-type mice. In a mouse model of experimental autoimmune encephalomyelitis, TREK-1-activating compounds such as riluzole and linseed oil decreased disease severity compared with no treatment. Next steps include developing selective TREK-1 activators.
Sanofi markets Rilutek riluzole to treat amyotrophic lateral sclerosis (ALS).

SciBX 6(35); doi:10.1038/scibx.2013.951
Published online Sept. 12, 2013

Unpatented; licensing status not applicable

Bittner, S. et al. Nat. Med.; published online Aug. 11, 2013;
doi:10.1038/nm.3303
Contact: Sven G. Meuth, University of Muenster, Muenster, Germany
e-mail:
sven.meuth@ukmuenster.de

Contact: Stefan Bittner, same affiliation as above
e-mail:
stefan.bittner@ukmuenster.de